Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers

Leakakos, Tina; Cheng, Jin; Lawson, Greg; Peterson, Caryn; Goodwin, Scott C.

doi:10.1007/s00280-003-0597-9

Cited by 74 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These can be doubled or even extended to several days with instillations enhanced by nanocarriers, in situ gels serving as drug depots, or a combination of both nanocarriers and hydrogels [47, 49–51, 61, 62]. Instillation of magnetic nanoparticles in the presence of an externally applied magnetic field has shown increased efficacy of doxorubicin against tumors in preclinical and in vivo studies [63, 64]. A similar approach, which combined Bacillus Calmette-Guérin (BCG) with a magnetic thermosensitive hydrogel and an external magnetic field, demonstrated continuous intravesical release of BCG over a 48 h period in a rat model.…”

Section: Bladder Drug Deliverymentioning

confidence: 99%

Single compartment drug delivery

Cima

Lee²,

Daniel³

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as “privileged,” since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective.

show abstract

Section: Bladder Drug Deliverymentioning

confidence: 99%

Single compartment drug delivery

Cima

Lee²,

Daniel³

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that the utilizing of nanoparticles in combination with EMF allows an effective destruction of malignant cells and provides a platform for drug and gene delivery (15,(86)(87)(88)(89)(90)(91). Various types of nano-carriers such as magnetic microsphere-methotrexate conjugates (92), micro-particles containing metallic iron and activated carbon (93), and magnetoliposomes have been proposed (94). Although all of them vary in size, structure, magnetic and thermal properties the application of magnetic nanoparticles mostly relies on generation of heat upon exposure to EMF, thus providing a basis for developing thermal bio-effects and release of loaded substances to the tissues.…”

Section: Thermal Bio-effects Caused By Electromagnetic Fields: Applicmentioning

confidence: 99%

Bio-effects of non-ionizing electromagnetic fields in context of cancer therapy

et al. 2014

View full text Add to dashboard Cite

Bio-effects mediated by non-ionizing electromagnetic fields (EMF) have become a hot topic of research in the last decades. This interest has been triggered by a growing public concern about the rapid expansion of telecommunication devices and possible consequences of their use on human health. Despite a feasibility study of potential negative impacts, the therapeutic advantages of EMF could be effectively harnessed for the treatment of cancer and other diseases. This review aims to examine recent findings relating to the mechanisms of action underlying the bio-effects induced by non-ionizing EMF. The potential of non-thermal and thermal effects is discussed in the context of possible applications for the induction of apoptosis, formation of reactive oxygen species, and increase of membrane permeability in malignant cells. A special emphasis has been put on the combination of EMF with magnetic nano-particles and ultrasound for cancer treatment. The review encompasses both human and animal studies.

show abstract

“…A recent study by Leakakos et al used MTC (with particle sizes of 0.5-5 mm) to deliver the anticancer drug, doxorubicin, into the bladder wall. 33 The MTC contained an iron component to allow targeting by a magnet, and an activated carbon component to adsorb the drug. Magnetic guiding of such particles might provide site-specific intravesical delivery of drugs.…”

Section: Magnetic Nanoparticlesmentioning

confidence: 99%

Intravesical drug delivery for dysfunctional bladder

2013

View full text Add to dashboard Cite

The bladder is a hollow organ that can be treated locally by transurethral catheter for intravesical drug instillation or cystoscopy for intravesical drug injection. With advancing technology, local organ-specific therapy and drug delivery is of expanding interest for treating dysfunctional bladder, including interstitial cystitis/bladder pain syndrome, overactive bladder and sterile hemorrhagic cystitis after chemotherapy or pelvic radiation. Intravesical therapy has shown varying degrees of efficacy and safety in treating interstitial cystitis/bladder pain syndrome, overactive bladder and hemorrhagic cystitis with new modalities being developed. Intravesical (regional) therapy has several advantages than oral (systemic) therapy, including high local concentration and less systemic toxicity. In recent years, intravesical delivery of biotechnological products including neurotoxins and immunosuppressive agents, and delivery platform including liposomes has shown promise for lower urinary tract symptoms. This review considers the current status of intravesical therapy in dysfunctional bladder including interstitial cystitis/bladder pain syndrome, overactive bladder and hemorrhagic cystitis with special attention to lipid based novel drug-delivery.

show abstract

Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers

Cited by 74 publications

References 8 publications

Single compartment drug delivery

Single compartment drug delivery

Bio-effects of non-ionizing electromagnetic fields in context of cancer therapy

Intravesical drug delivery for dysfunctional bladder

Contact Info

Product

Resources

About